AIM
CRMD icon

Acrospire Investment Management’s CorMedix CRMD Stock Holding History

Acrospire Investment Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-777
Closed -$6K – 2251
2016
Q4 		$6K Buy
777
+422
+119% +$4.27K ﹤0.01% 2029
2016
Q3 		$4K Buy
+355
New +$3.32K ﹤0.01% 1849
2016
Q2 		– Sell
-201
Closed -$3K – 2053
2016
Q1 		$3K Buy
+201
New +$1.95K ﹤0.01% 1913

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GLRA
Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Acrospire Investment Management's CRMD Position: Q1 2017 in Review

Acrospire Investment Management sold out of CorMedix (CRMD) in Q1 2017, closing a stake of 777 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in CRMD in Q1 2016 and held it in 3 quarters. The position peaked at $6K in Q4 2016. 30 funds tracked by Wall St. Rank hold CRMD as of Q1 2017.

  • Acrospire Investment Management reported no remaining CorMedix position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 777 CorMedix shares in Q1 2017, an estimated $6K.
  • Acrospire Investment Management first reported a position in CorMedix in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's CorMedix position peaked at $6K in Q4 2016.
  • 30 funds tracked by Wall St. Rank held CorMedix as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.